Lnc-C9orf53-2:1

Please input one-sentence summary here.

Annotated Information

Transcriptomic Nomeclature

Please input transcriptomic nomeclature information here.

Function

Please input function information here.

Regulation

Please input regulation information here.

Expression

Please input expression information here.

Allelic Information and Variation

Please input allelic information and variation information here.

Evolution

Please input evolution information here.

You can also add sub-section(s) at will.

Labs working on this lncRNA

Please input related labs here.

References

Please input cited references here.

Basic Information

Transcript ID	lnc-C9orf53-2:1
Source	LNCipedia2.1
Same with	,
Classification	intergenic
Length	503 nt
Genomic location	chr9+:21994789..22029563
Exon number	,
Exons	,
Genome context
Sequence	000001 AGCTACATCC GTCACCTGAC ACGGCCCTAC CAGGAACAGC CGCGCTCCCG CGGATTCTGG TGCTGCTCGC GTCCCCGCTC 000080 000081 CCCTATTCCC CTTATTTTAT TCCTGGCTCC CCTCGTCGAA AGTCTTCCAT TCTTCAAACT AGATTATTTA AAAATGAAAA 000160 000161 AGGAAGAAAG GAAAGCGAGG TCATCTCATT GCTCTATCCG CCAATCAGGA GGCTGAATGT CAGTTTTGAA CTAAAAGCCG 000240 000241 CTCCGCTCCT CTTCTAGATT TGGAAAACAA GCGAAATTAA ACTAAACCGC TGCACGCCTC TGACGCGACA TCTGGACACG 000320 000321 GCGCGGCGCT GGCGCTGCCG GAGCTGTCGA CCCGGCCTGG CGCCGGACTA GGACTATTTG CCACAACATT TCAAAGGATT 000400 000401 CCAAGAGAGA ATATTGGTGT CCATGCTGTG ATGATTCCTC AGCTCCTCTC ATCTGATCTC CGTCCTGGCC CCCATGACTT 000480 000481 TCTTTGTGGT AGTTAAGGTG TGG

[back to top]

Annotation (From lncRNAdb)

[lnc-C9orf53-2:1]

Section	Description
ID	ANRIL
Characteristics	Present in multiple splicing isoforms (Folkersen (2009)) (such as the CDK2BAS RefSeq sequence NR_003529.3 of ~3.9kb). Also detected as an unspliced transcript of 34.8 kb (Yu (2008)), specified as p15AS, but which seems to correspond to an isoform with the first intron of CDK2BAS retained. Antisense to the tumor suppressor gene p15/CDKN2A. (Yu (2008)). Traverses a noncoding region centromeric to CDKN2A, a region containing the INK4b/ARF/INK4a locus and implicated in a range of complex diseases including cancer (such as melanoma-neural system tumor syndrome), type 2 diabetes, periodontitis and coronary heart disease (see extensive reference list in Literature below, and Popov (2010) for a review). Transcript found to be quite unstable with a half-life >4 hr in human Hela cells (Tani (2012)).
Expression	Expressed in tissues and cell types affected by atherosclerosis. Increased levels of ANRIL are found in patients carrying the atherosclerosis risk haplotype expression, including in peripheral blood mononuclear cells, whole blood and atherosclerotic plaque tissue, and the levels were directly correlated with the severity of atherosclerosis (Holdt (2010)). Up-regulated in prostate cancer (Yap (2010)).
Function	In vitro over-expression of p15as/ANRIL RNA was originally demonstrated to induce epigenetic silencing of p15 gene expression (Yu (2008)). Recently, ANRIL RNA was found to interact and regulate chromobox 7 (CBX7), a component of the Polycomb Repressor Complex 1 (PRC1), which methylates histone H3 lysine 27 to promote epigenetic silencing, and is also up-regulated in prostate cancer. Interaction occurs with a conserved chromodomain of CBX7 and is essential for the ability of PRC1 to repress the INK4b/ARF/INK4a locus and control cell senescence. (Yap (2010))
Name	ANRIL: Antisense noncoding RNA in the INK4 locus;. CDKN2B-AS1: CDKN2B antisense RNA 1;. P15AS: P15 antisense RNA

[back to top]